Bolt Biotherapeutics receives Nasdaq bid price deficiency notice; 180 days to comply

Bolt Biotherapeutics, Inc.

Avg closing price of common stock fell below $1.00 over prior 30 trading days as of July 1, 2024.
180-day grace period until Dec 30, 2024 to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not compliant, may qualify for an additional 180-day extension if other listing standards met.
Company intends to monitor bid price and evaluate options including potential reverse stock split.
Notice has no immediate effect on listing; stock continues trading on Nasdaq Global Select Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.